Stockscreener 앱 받기
179.43
0.19%
-0.35
Quest Diagnostics Inc 주식(DGX)의 최신 뉴스
DGX Stock Up on New Blood Test Development Deal With MD Anderson - TradingView
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Quest Diagnostics stock hits all-time high of $180.11 By Investing.com - Investing.com Canada
Quest Diagnostics and University of Texas want to promote more cancer screenings - Mugglehead Magazine
Fecal Immunochemical Diagnostic Test (FIT) Market Top - openPR.com
Quest Diagnostics (DGX) Collaborates with MD Anderson for Cancer Risk Test Development | DGX Stock News - GuruFocus
Quest Diagnostics New Blood Test Could Transform Early Cancer Detection for 9 Major Cancers - Stock Titan
Quest Diagnostics Incorporated : The stock forcefully approaches new pivot levels - MarketScreener
Quest Diagnostics (DGX) Stock Analysis: Navigating a 5.5% Upside with Strong Revenue Growth - DirectorsTalk Interviews
Transcript : Quest Diagnostics Incorporated Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - marketscreener.com
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Participates in Upcoming Oppenheimer Meeting | DGX Stock News - GuruFocus
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick? - The Globe and Mail
Is Wall Street Bullish or Bearish on Quest Diagnostics Stock? - inkl
Is Wall Street Bullish Or Bearish On Quest Diagnostics Stock? - Barchart.com
Quest Diagnostics' $4M Rest Break Settlement Gets Initial OK - Law360
Quest Diagnostics (DGX) Announces Results of 2025 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics Inc (DGX) Shares Gap Down to $171.44 on May 21 - GuruFocus
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year? - Yahoo Finance
Quest Diagnostics stock hits all-time high of $179.37 By Investing.com - Investing.com Nigeria
Director Diaz Luis was granted 1,203 shares, increasing direct ownership by 42% to 4,054 units (SEC Form 4) - Quantisnow
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference - PR Newswire
Lung Cancer Diagnostics Market Outlook: Opportunities in Early - openPR.com
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock - Yahoo Finance
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Insider Sell: Mark Delaney Sells Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics Keeps Dividend at $0.80 per Share, Payable July 21 to Shareholders as of July 7 - marketscreener.com
Quest Diagnostics (DGX) Declares Consistent Dividend - GuruFocus
Quest Diagnostics Declares Quarterly Cash Dividend - PR Newswire
Quest Diagnostics : Forbes Names Quest Diagnostics One of America's Best Large Employers - marketscreener.com
Is Quest Diagnostics Incorporated's (NYSE:DGX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo
Should You Continue to Retain DGX Stock in Your Portfolio? - TradingView
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds - Quantisnow
DGX Q1 Earnings Call: Acquisitions, Advanced Diagnostics, and Operational Initiatives Drive Growth - Yahoo Finance
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics (DGX) Sees Raised Target Price by JP Morgan | - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Quest Diagnostics (DGX) Receives Price Target Increase from JPMo - GuruFocus
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha
Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360
Bullish on Quest Diagnosis Inc. - The Globe and Mail
This Company Extended Its Post-Earnings Rally to Record Highs - The Globe and Mail
Labcorp beats quarterly profit estimate on diagnostic test demand - Reuters
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com
0.96%
자본화:
|
볼륨(24시간):